Chairperson of the Egyptian Drug Authority (EDA) Ali Ghamrawy has held a bilateral meeting with President of the Saudi Food and Drug Authority (SFDA) Hisham Aljadhey on the sidelines of the 2025 International Coalition of Medicines Regulatory Authorities (ICMRA) Summit, held in Amsterdam, the Netherlands. The Saturday meeting reviewed progress in implementing cooperation mechanisms between the two authorities in the pharmaceutical field and explored opportunities to expand joint coordination in regional regulatory areas of mutual interest. Discussions also focused on the importance of digital transformation and the use of artificial intelligence technologies to enhance the efficiency of pharmaceutical and medical supply regulatory systems—thereby improving responsiveness and alignment with global developments in this vital sector. Ghamrawy reaffirmed the EDA's commitment to strengthening cooperation with Arab and international regulatory bodies to develop the pharmaceutical oversight system and exchange expertise in line with the latest global standards. He noted that Saudi Arabia is a key strategic partner for Egypt in the pharmaceutical sector, underscoring the importance of continued coordination to enhance regulatory capacities and promote Arab integration, which contributes to improving the quality and safety of pharmaceutical products across the region. For his part, SFDA President Hisham Aljadhey emphasised Saudi Arabia's keenness to deepen regional partnerships and exchange expertise with leading regulatory authorities—chief among them the EDA—to support the healthcare and pharmaceutical sectors and achieve the highest standards of quality and safety. Both sides stressed the importance of building on their cooperation to strengthen regulatory capacities and intensify joint efforts to promote Arab integration in the pharmaceutical field, particularly in light of Saudi Arabia's advanced regulatory framework, which ranks among the most prominent in the region. The meeting forms part of the EDA's broader strategy to reinforce international partnerships, develop regulatory policies, and enhance the global competitiveness of Egypt's pharmaceutical industry. It also reflects the Authority's commitment to consolidating its position as a leading regional regulatory body and contributing to the goals of Egypt Vision 2030 through the development of a robust and globally aligned pharmaceutical system.
